GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Financiere de Tubize SA (LTS:0D53) » Definitions » Quality Rank

Financiere de Tubize (LTS:0D53) Quality Rank


View and export this data going back to 2007. Start your Free Trial

What is Financiere de Tubize Quality Rank?

The Quality Rank measures the business quality of a company relative to other companies. It is ranked based on the strength of the balance sheet, as well as the profitability and growth of the business. The ranked companies are split in equal numbers and then ranked from 1 to 10, with 10 being the highest.

The rank of balance sheet (30%)

The rank of balance sheet is done through the ranking of:
  • Interest coverage
  • Zscore
  • Debt to revenue
  • Equity to asset
  • Cash to debt

The rank of Profitability (70%)

The ranking of Profitability is done by ranking:
  • Operating margin mean rank (10-year mean average profit margine)
  • Operating margin growth rank
  • Fscore
  • Predictability rank
  • Revenue growth rank (5 year), when the growth is higher than 25%, set it as 25%
  • Num of year profit (number of years that is profitable within the last 10 years)
  • ROIC median (10-year median of ROIC)

Financiere de Tubize Quality Rank Related Terms

Thank you for viewing the detailed overview of Financiere de Tubize's Quality Rank provided by GuruFocus.com. Please click on the following links to see related term pages.

Financiere de Tubize (LTS:0D53) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Financiere de Tubize SA (LTS:0D53) » Definitions » Quality Rank
Comparable Companies
XBRU:HYL XBRU:ONWD XBRU:ALIMG XBRU:CYAD XBRU:BIOS XBRU:OXUR XBRU:ARGX OCSE:NOVO B VRTX REGN ASX:CSL MRNA XKRX:207940 XKRX:068270 XBRU:UCB BNTX ALNY OCSE:GMAB BGNE BMRN
Traded in Other Exchanges
FTD:Germany TUB:Belgium
Address
Allée de la Recherche, 60, Brussels, BEL, 1070
Website
https://www.financiere-tubize.be
Financiere de Tubize SA is a holding company that owns a stake in UCB, a biopharmaceutical company. UCB is a global biotechnology company that develops treatments for conditions related to neurology and immunology. UCB generates the vast majority of its revenue in the United States, followed by Europe and other international markets. Most of its sales revenue is derived from its neurology products, followed by its immunology products. The company's strategy focuses on leveraging scientific advances and skills in areas such as genetics, biomarkers, and human biology.